finance · FINANCIAL RISK SIGNALS · severity 4/5 · 90% confidence
Q1 2026 EPS of -$0.57 Indicates High Net Spending
AIM ImmunoTech — Public Companies
What happened
AIM ImmunoTech reported an EPS of -$0.57 for Q1 2026, reflecting significant net losses driven by ongoing R&D investment.
Agent reasoning
The article explicitly states the EPS was -$0.57, attributed to increased clinical trial site investments [2]. This indicates sustained pre-revenue operations with high burn rate.